Even though much of Stephen Hahn's 20 November Senate confirmation hearing to become commissioner of the US Food and Drug Administration focused on e-cigarettes, a plurality of actual questions directed to the MD Anderson chief medical executive focused on drug development issues, similar to Scott Gottlieb's confirmation hearing in 2017.
Many members of the Senate Health, Education, Labor and Pensions Committee discussed the FDA's regulation of e-cigarettes, but a Pink Sheet analysis of the 67 questions asked by committee members identified 13 questions related to drug development
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?